China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced that the National Medical Products Administration (NMPA) has accepted for review the Abbreviated New Drug Application (ANDA) for NVK002, an atropine external use eye solution aimed at pediatric myopia progression.
NVK002: A Novel Ophthalmic Solution for Myopia Control
NVK002 is an investigational novel topical ophthalmic solution designed to control the progression of myopia in children and adolescents. This preservative-free formulation is anticipated to have a shelf life of over 24 months, offering a long-term solution for patients. The product has been developed to cater to a wide patient group, covering children and adolescents aged 3 to 17, making it one of the most extensive patient group coverages in this therapeutic area.
Advancing Pediatric Ophthalmic Care
The acceptance of the ANDA for NVK002 by the NMPA is a significant step forward in advancing pediatric ophthalmic care. This development highlights Zhaoke Ophthalmology’s commitment to addressing the growing concerns surrounding myopia progression in younger demographics and underscores the company’s efforts in bringing innovative solutions to the market.-Fineline Info & Tech
